Compare Amphastar Pharmaceuticals Inc (AMPH) vs Cenovus Energy Inc (CVE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Cenovus Energy Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Cenovus Energy Inc trades at $29.72 (market cap $54.43B). The key difference: Cenovus Energy Inc is far larger — about 63× Amphastar Pharmaceuticals Inc's market cap, and Cenovus Energy Inc pays a 2.11% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CVE | |
|---|---|---|
Market Cap | $863.95M | $54.43B |
Sector | Health | Energy |
52-Week High | $30.81 | $31.80 |
52-Week Low | $16.87 | $14.50 |
Enterprise Value | $1.26B | $60.50B |
Dividend Yield | — | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Cenovus Energy (CVE) trades at $28.25, showing neutral momentum with strong fundamental metrics including a P/E of 10.99 and ROE of 20.96%. Recent Q2 2026 earnings matched expectations at $1.11 EPS, while revenue and production growth remain robust. Technical indicators show mixed signals with RSI neutral and moving averages bullish, trading near key support at $28.
The outlook remains positive with projected 2026 revenue growth to $58B and net income of $6.7B, supported by strong cash flow generation. Risks include oil price volatility and refining pressures, but analyst consensus leans bullish with 40.7% buy ratings. The stock presents value opportunity given attractive valuation multiples and dividend yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →
